# EDGAR Filing Document

**Accession Number:** 0001279704
**File Stem:** 0001104659-25-063940
**Filing Date:** 2025-6
**Character Count:** 2472
**Document Hash:** 833289eccf5130378aa0cc68356dfff9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-063940.hdr.sgml**: 20250730

**ACCESSION NUMBER**: 0001104659-25-063940

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250630

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cellectar Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001279704
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 043321804
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 100 CAMPUS DRIVE
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932
- **BUSINESS PHONE:** (608) 441-8120

**MAIL ADDRESS:**
- **STREET 1:** 100 CAMPUS DRIVE
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NOVELOS THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20050617

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** COMMON HORIZONS INC
- **DATE OF NAME CHANGE:** 20040211

**CELLECTAR BIOSCIENCES, INC.**

**100 Campus Drive**

**Florham Park, New Jersey 07932**

June 30, 2025

**<u>VIA EDGAR</u>**

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| Re: | Cellectar Biosciences, Inc. |
|  | Registration Statement on Form S-1/A |
|  | Filed June 30, 2025 |
|  | File No. 333-288333 |

---

Ladies and Gentlemen:

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Cellectar Biosciences, Inc., a Delaware corporation (the "Company"), hereby requests that the effective date of the Company's Registration Statement on Form S-1/A (Registration No. 333-288333), be accelerated so that the Registration Statement will become effective at 9:00 a.m. on July 1, 2025, or as soon as practicable thereafter.

The cooperation of the staff in meeting our request is very much appreciated. If you have any questions or comments, please contact Kostian Ciko (212-839-5450 or <u>kciko@sidley.com</u>). Thank you for your assistance with these matters.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| CELLECTAR BIOSCIENCES, INC. | CELLECTAR BIOSCIENCES, INC. |
| By: | /s/ Chad J. Kolean |
|  | Chad J. Kolean, Chief Financial Officer |

---

---

| | |
|:---|:---|
| cc: | James V. Caruso |
|  | Asher M. Rubin |
|  | Istvan A. Hajdu |
|  | Kostian Ciko |

---